---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-001168"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2022-02-14T23:59:59+00:00"
generated_at: "2026-06-27T08:21:31.523846+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Biodesix reports record full-year 2021 revenue of $54.5M; core lung diagnostic testing up 49%

## Summary
- Full-year 2021 total revenue $54.5M vs $45.6M in 2020; Q4 revenue $7.2M.
- Core lung diagnostic testing revenue grew 49% YoY; excluding COVID-19, annual core revenue $24.3M (+41%).
- Q4 core revenue (ex-COVID) $6.8M, up 22% YoY and 13% sequentially.
- Cash and cash equivalents $32.7M as of Dec 31, 2021.
- CEO highlights new IQLung and GeneStrat NGS tests; company may seek additional capital.

## SEC filing metadata
- accession: 0000950170-22-001168
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2022-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017022001168/0000950170-22-001168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017022001168/bdsx-20220214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-001168
- JSON: https://secwatch.observer/filing/0000950170-22-001168.json
- Plain text: https://secwatch.observer/filing/0000950170-22-001168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.